AAPL323.12+6.27 (+1.98%) ▲|ABBV259.94+3.52 (+1.37%) ▲|ABT109.72-0.65 (-0.58%) ▼|ACN188.13-1.63 (-0.86%) ▼|ADBE288.66-4.13 (-1.41%) ▼|AMAT444.40-13.99 (-3.05%) ▼|AMD457.06-13.66 (-2.90%) ▼|AMGN433.06+3.18 (+0.74%) ▲|AMT175.51-0.19 (-0.11%) ▼|AMZN254.66-5.12 (-1.97%) ▼|AVGO367.78-2.56 (-0.69%) ▼|AXP326.86-3.32 (-1.00%) ▼|BA206.77-1.01 (-0.49%) ▼|BAC62.37+0.43 (+0.69%) ▲|BKNG199.46+0.37 (+0.18%) ▲|BLK1,136.45-19.16 (-1.66%) ▼|BMY67.03+0.22 (+0.32%) ▲|BNY160.60-0.68 (-0.42%) ▼|BRK-B504.70+0.67 (+0.13%) ▲|C133.09+1.47 (+1.11%) ▲|CAT781.69-15.78 (-1.98%) ▼|CL90.56+0.74 (+0.83%) ▲|CMCSA26.55-0.07 (-0.26%) ▼|COF213.56-0.96 (-0.45%) ▼|COP135.00+2.51 (+1.89%) ▲|COST945.38+1.49 (+0.16%) ▲|CRM257.80+0.26 (+0.10%) ▲|CSCO109.17-1.33 (-1.20%) ▼|CVS97.09+3.18 (+3.39%) ▲|CVX208.95+2.81 (+1.36%) ▲|DE672.81+17.90 (+2.73%) ▲|DHR209.33-4.24 (-1.98%) ▼|DIS107.52-0.03 (-0.03%) ▼|DUK120.65+0.74 (+0.61%) ▲|EMR149.65-2.79 (-1.83%) ▼|FDX324.60-2.80 (-0.86%) ▼|GD369.27-2.09 (-0.56%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV884.54-13.99 (-1.56%) ▼|GILD148.38+2.04 (+1.39%) ▲|GM86.22-0.10 (-0.12%) ▼|GOOG332.96-2.45 (-0.73%) ▼|GOOGL336.07-3.29 (-0.97%) ▼|GS1,021.55+0.65 (+0.06%) ▲|HD321.78-6.06 (-1.85%) ▼|HON210.33-3.20 (-1.50%) ▼|IBM231.12-2.75 (-1.18%) ▼|INTC88.80-0.71 (-0.79%) ▼|INTU349.87-9.43 (-2.62%) ▼|ISRG368.92-7.94 (-2.11%) ▼|JNJ268.15+2.30 (+0.86%) ▲|JPM358.40+2.38 (+0.67%) ▲|KO88.53-0.14 (-0.16%) ▼|LIN483.89-5.69 (-1.16%) ▼|LLY1,171.93+15.20 (+1.31%) ▲|LMT551.37-6.41 (-1.15%) ▼|LOW201.78-2.92 (-1.43%) ▼|LRCX291.64-9.85 (-3.27%) ▼|MA587.12-2.19 (-0.37%) ▼|MCD261.14-0.54 (-0.21%) ▼|MDLZ62.38+0.31 (+0.50%) ▲|MDT91.80+1.15 (+1.27%) ▲|META578.60+6.26 (+1.09%) ▲|MMM170.74-1.09 (-0.63%) ▼|MO70.38+1.90 (+2.77%) ▲|MRK149.39+1.63 (+1.10%) ▲|MS214.04+0.72 (+0.34%) ▲|MSFT501.12-6.18 (-1.22%) ▼|MU954.46-4.28 (-0.45%) ▼|NEE82.79+0.45 (+0.55%) ▲|NFLX80.88-0.18 (-0.22%) ▼|NKE38.36-0.30 (-0.76%) ▼|NOW143.09-4.91 (-3.31%) ▼|NVDA218.48-2.02 (-0.92%) ▼|ORCL142.52-6.60 (-4.43%) ▼|PEP140.01-0.33 (-0.24%) ▼|PFE28.64+0.18 (+0.61%) ▲|PG147.83+2.71 (+1.87%) ▲|PLTR183.27-3.11 (-1.67%) ▼|PM190.77+3.47 (+1.85%) ▲|QCOM165.61-4.87 (-2.86%) ▼|RTX206.16-1.58 (-0.76%) ▼|SBUX105.83-0.42 (-0.40%) ▼|SCHW108.78-1.04 (-0.95%) ▼|SO88.11+0.11 (+0.13%) ▲|SPG213.04+0.72 (+0.34%) ▲|T26.07+0.18 (+0.70%) ▲|TMO604.86-12.24 (-1.98%) ▼|TMUS181.95+1.51 (+0.84%) ▲|TSLA359.27-8.68 (-2.36%) ▼|TXN253.38-7.53 (-2.89%) ▼|UBER75.44-0.21 (-0.28%) ▼|UNH395.95+6.54 (+1.68%) ▲|UNP293.91-6.76 (-2.25%) ▼|UPS102.78-1.46 (-1.40%) ▼|USB61.23-0.36 (-0.58%) ▼|V376.86-2.52 (-0.66%) ▼|VZ50.30+0.28 (+0.55%) ▲|WFC86.87+0.48 (+0.55%) ▲|WMT106.07+1.20 (+1.14%) ▲|XOM163.12+2.17 (+1.35%) ▲|AAPL323.12+6.27 (+1.98%) ▲|ABBV259.94+3.52 (+1.37%) ▲|ABT109.72-0.65 (-0.58%) ▼|ACN188.13-1.63 (-0.86%) ▼|ADBE288.66-4.13 (-1.41%) ▼|AMAT444.40-13.99 (-3.05%) ▼|AMD457.06-13.66 (-2.90%) ▼|AMGN433.06+3.18 (+0.74%) ▲|AMT175.51-0.19 (-0.11%) ▼|AMZN254.66-5.12 (-1.97%) ▼|AVGO367.78-2.56 (-0.69%) ▼|AXP326.86-3.32 (-1.00%) ▼|BA206.77-1.01 (-0.49%) ▼|BAC62.37+0.43 (+0.69%) ▲|BKNG199.46+0.37 (+0.18%) ▲|BLK1,136.45-19.16 (-1.66%) ▼|BMY67.03+0.22 (+0.32%) ▲|BNY160.60-0.68 (-0.42%) ▼|BRK-B504.70+0.67 (+0.13%) ▲|C133.09+1.47 (+1.11%) ▲|CAT781.69-15.78 (-1.98%) ▼|CL90.56+0.74 (+0.83%) ▲|CMCSA26.55-0.07 (-0.26%) ▼|COF213.56-0.96 (-0.45%) ▼|COP135.00+2.51 (+1.89%) ▲|COST945.38+1.49 (+0.16%) ▲|CRM257.80+0.26 (+0.10%) ▲|CSCO109.17-1.33 (-1.20%) ▼|CVS97.09+3.18 (+3.39%) ▲|CVX208.95+2.81 (+1.36%) ▲|DE672.81+17.90 (+2.73%) ▲|DHR209.33-4.24 (-1.98%) ▼|DIS107.52-0.03 (-0.03%) ▼|DUK120.65+0.74 (+0.61%) ▲|EMR149.65-2.79 (-1.83%) ▼|FDX324.60-2.80 (-0.86%) ▼|GD369.27-2.09 (-0.56%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV884.54-13.99 (-1.56%) ▼|GILD148.38+2.04 (+1.39%) ▲|GM86.22-0.10 (-0.12%) ▼|GOOG332.96-2.45 (-0.73%) ▼|GOOGL336.07-3.29 (-0.97%) ▼|GS1,021.55+0.65 (+0.06%) ▲|HD321.78-6.06 (-1.85%) ▼|HON210.33-3.20 (-1.50%) ▼|IBM231.12-2.75 (-1.18%) ▼|INTC88.80-0.71 (-0.79%) ▼|INTU349.87-9.43 (-2.62%) ▼|ISRG368.92-7.94 (-2.11%) ▼|JNJ268.15+2.30 (+0.86%) ▲|JPM358.40+2.38 (+0.67%) ▲|KO88.53-0.14 (-0.16%) ▼|LIN483.89-5.69 (-1.16%) ▼|LLY1,171.93+15.20 (+1.31%) ▲|LMT551.37-6.41 (-1.15%) ▼|LOW201.78-2.92 (-1.43%) ▼|LRCX291.64-9.85 (-3.27%) ▼|MA587.12-2.19 (-0.37%) ▼|MCD261.14-0.54 (-0.21%) ▼|MDLZ62.38+0.31 (+0.50%) ▲|MDT91.80+1.15 (+1.27%) ▲|META578.60+6.26 (+1.09%) ▲|MMM170.74-1.09 (-0.63%) ▼|MO70.38+1.90 (+2.77%) ▲|MRK149.39+1.63 (+1.10%) ▲|MS214.04+0.72 (+0.34%) ▲|MSFT501.12-6.18 (-1.22%) ▼|MU954.46-4.28 (-0.45%) ▼|NEE82.79+0.45 (+0.55%) ▲|NFLX80.88-0.18 (-0.22%) ▼|NKE38.36-0.30 (-0.76%) ▼|NOW143.09-4.91 (-3.31%) ▼|NVDA218.48-2.02 (-0.92%) ▼|ORCL142.52-6.60 (-4.43%) ▼|PEP140.01-0.33 (-0.24%) ▼|PFE28.64+0.18 (+0.61%) ▲|PG147.83+2.71 (+1.87%) ▲|PLTR183.27-3.11 (-1.67%) ▼|PM190.77+3.47 (+1.85%) ▲|QCOM165.61-4.87 (-2.86%) ▼|RTX206.16-1.58 (-0.76%) ▼|SBUX105.83-0.42 (-0.40%) ▼|SCHW108.78-1.04 (-0.95%) ▼|SO88.11+0.11 (+0.13%) ▲|SPG213.04+0.72 (+0.34%) ▲|T26.07+0.18 (+0.70%) ▲|TMO604.86-12.24 (-1.98%) ▼|TMUS181.95+1.51 (+0.84%) ▲|TSLA359.27-8.68 (-2.36%) ▼|TXN253.38-7.53 (-2.89%) ▼|UBER75.44-0.21 (-0.28%) ▼|UNH395.95+6.54 (+1.68%) ▲|UNP293.91-6.76 (-2.25%) ▼|UPS102.78-1.46 (-1.40%) ▼|USB61.23-0.36 (-0.58%) ▼|V376.86-2.52 (-0.66%) ▼|VZ50.30+0.28 (+0.55%) ▲|WFC86.87+0.48 (+0.55%) ▲|WMT106.07+1.20 (+1.14%) ▲|XOM163.12+2.17 (+1.35%) ▲|
24.1 C
New York
Tuesday, September 1, 2026

Tag: medicine

newssourceFORcompanyinformationcontent1releasesmarket

Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®

Strong recruitment momentum demonstrated in 2026 Year-to-date recruitment has already surpassed total enrollment for 2025OSLO, Norway, June 18, 2026 /PRNewswire/ -- Oncoinvent, a clinical-stage...

F2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in...


MANCHESTER, United Kingdom and OSAKA, Japan, June 18, 2026 (GLOBE NEWSWIRE) -- F2G Ltd and Shionogi & Co., Ltd (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) (“Shionogi”) today announced positive topline results from the global Phase 3 OASIS study (NCT05101187), comparing the investigational oral antifungal drug olorofim versus AmBisome® (liposomal amphotericin B for injection) followed by standard of care (SOC) in patients with invasive aspergillosis whose infection is either refractory to or unsuitable for azole therapy.

SEEKINK Unveils Full Product Portfolio of E-Paper Solutions at Infocomm 2026, Powering Commercial, Workplace, Consumer Electronics, Smarter Transit Applications

From the Prism 3S tiled decorative wall to small tags - ePaper Innovation Scales Across Every SurfaceLAS VEGAS, June 17, 2026 /PRNewswire/ -- Infocomm...

AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial

SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech,...

Mother Nature AI Reveals Three-Specialist AI Platform as It Approaches 5 Million Users and Launches $8.5 Million Capital Raise

New York health technology company combines general wellness, mental health, and nutrition AI into a single personalized ecosystem - and prepares its Vital IQ™ wearable for market 
New York health technology company combines general wellness, mental health, and nutrition AI into a single personalized ecosystem - and prepares its Vital IQ™ wearable for market

LUPINE CREST CAPITAL, FAMILY OFFICE OF JP CONTE, SIGNIFICANTLY INCREASES INVESTMENT IN BRAZILIAN WASTE-TO-ENERGY COMPANY ORIZON

Lupine Crest invests an additional ~R$70M (~$14M USD) in OrizonSÃO PAULO and ASPEN, Colo., June 17, 2026 /PRNewswire/ -- Lupine Crest Capital, the family...

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Reported positive clinical proof-of-concept data for OD-001 in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis.

uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease

~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~

Matricelf Advances Toward First in Human Trial Following Successful GLP Safety Study Completion

TEL AVIV, Israel, June 17, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury,...

SHINE and newcleo Partner to Advance U.S. Spent Nuclear Fuel Recycling

JANESVILLE, Wis. and PARIS, June 17, 2026 (GLOBE NEWSWIRE) -- SHINE, a fusion energy company with a platform expanding into nuclear fuel recycling, and newcleo, a developer of advanced nuclear reactors and fuel, today announced an agreement to collaborate on advancing innovative technologies for the recycling of used nuclear fuel.

Lovense Calls for “Closing the Gap Takes Two” Amid a Decades-Old Orgasm Gap

LOS ANGELES, June 17, 2026 /PRNewswire/ -- If you've ever finished sex and thought "that was fine" while knowing, somewhere deeper, that it wasn't...

SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares

BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the pricing...

GuideAI Health Corp. Announces Closing of Business Combination, Subscription Receipt Offering, and Filing of Final Prospectus

Not for distribution to U.S. Newswire services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

RRS® HA Long Lasting awarded Best Injectable in Skin Revitalization at AMWC 2026, reinforcing Skin Tech Pharma Group’s leadership in the Skin Builder category

BARCELONA, Spain, June 17, 2026 /PRNewswire/ -- Skin Tech Pharma Group proudly announces that its flagship injectable, RRS® HA LONG LASTING, has been recognized...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicine

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers